VolitionRx's (VNRX) "Buy" Rating Reaffirmed at D. Boral Capital

D. Boral Capital restated their buy rating on shares of VolitionRx (NYSE:VNRX - Free Report) in a research note issued to investors on Wednesday morning,Benzinga reports. The brokerage currently has a $5.00 target price on the stock.

VNRX has been the topic of a number of other research reports. StockNews.com started coverage on shares of VolitionRx in a report on Thursday, January 23rd. They set a "sell" rating on the stock. Benchmark reiterated a "hold" rating on shares of VolitionRx in a research note on Friday, November 22nd.

VolitionRx Price Performance

VolitionRx stock traded down $0.03 during mid-day trading on Wednesday, reaching $0.60. The stock had a trading volume of 85,602 shares, compared to its average volume of 95,968. VolitionRx has a one year low of $0.43 and a one year high of $1.23. The company has a 50-day moving average price of $0.63 and a two-hundred day moving average price of $0.66. The company has a market capitalization of $55.14 million, a price-to-earnings ratio of -1.65 and a beta of 1.20.

Insider Activity

In other news, CEO Cameron John Reynolds purchased 139,811 shares of the company's stock in a transaction dated Monday, December 9th. The shares were purchased at an average cost of $0.57 per share, for a total transaction of $79,692.27. Following the purchase, the chief executive officer now directly owns 2,117,404 shares in the company, valued at approximately $1,206,920.28. This represents a 7.07 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Guy Archibald Innes acquired 174,764 shares of VolitionRx stock in a transaction that occurred on Monday, December 9th. The shares were purchased at an average price of $0.57 per share, with a total value of $99,615.48. Following the transaction, the director now owns 617,085 shares of the company's stock, valued at $351,738.45. The trade was a 39.51 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 358,266 shares of company stock valued at $204,212 in the last 90 days. 12.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Ground Swell Capital LLC grew its holdings in VolitionRx Limited (NYSE:VNRX - Free Report) by 78.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 45,959 shares of the company's stock after acquiring an additional 20,249 shares during the period. Ground Swell Capital LLC's holdings in VolitionRx were worth $28,000 as of its most recent SEC filing. Institutional investors own 8.09% of the company's stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.